Your Complete Wegovy vs Mounjaro Switching Guide
Why Patients Switch Between Wegovy or Mounjaro for Weight Loss
Switching between Wegovy and Mounjaro for weight loss has become increasingly common as patients discover which treatment better suits their lifestyle and budget. The primary reasons include cost considerations, with different pricing structures affecting long-term affordability. Some patients experience varying side effect profiles between semaglutide and tirzepatide, leading them to explore alternatives. Storage requirements also influence choice—Wegovy offers superior travel convenience with 6 weeks room temperature stability versus Mounjaro's 21-day limit.
Additionally, availability fluctuations in the UK market sometimes necessitate temporary switches to maintain treatment continuity. Both prescription-only medicines work through GLP-1 pathways, but Mounjaro's dual GIP mechanism creates subtle differences in appetite control and tolerability. EverydayMeds stocks both options, ensuring patients can switch seamlessly without changing pharmacy providers. Your prescriber will determine the most appropriate transition protocol based on your current dose and treatment response.
Wegovy vs Mounjaro Pricing: Complete Cost Comparison for Weight Loss
When comparing Wegovy or Mounjaro for weight loss costs, pricing structures differ significantly between the medications. Wegovy pricing at EverydayMeds starts at £79.99 for the 0.25mg starter dose, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the maintenance 2.4mg dose. Our Getting Started bundles provide convenience, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, covering your first 8 weeks. New customers save with code FIRST40, while returning customers use DOSE25, both applied at checkout to reach these final prices.
Mounjaro follows a different dose progression, making direct price comparisons complex when switching medications. However, patients often find Wegovy's established dosing schedule more predictable for budgeting purposes. Our consistency bundles offer extended supply options—for example, Consistency 2.4mg (×2 pens) costs £419.99 for patients established on maintenance dosing. Both treatments require prescription-only medicine protocols, but EverydayMeds' transparent pricing eliminates surprises during your switching journey.
Clinical Evidence: How Wegovy or Mounjaro Perform in Weight Loss Studies
Clinical trials demonstrate both Wegovy and Mounjaro's effectiveness for weight loss, though direct head-to-head comparisons remain limited due to different study designs. The STEP trials showed patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in STEP 1, while STEP 5 demonstrated sustained 15.2% weight reduction at two years. These results established semaglutide's robust evidence base for long-term weight management.
Mounjaro's SURMOUNT trials indicated impressive results with the dual GIP/GLP-1 mechanism, though comparing percentage outcomes directly would be misleading given varying trial populations and endpoints. Both medications require alongside a reduced-calorie diet and increased physical activity to achieve optimal results. When switching between Wegovy or Mounjaro for weight loss, your prescriber will consider your individual response history rather than population averages to guide treatment decisions.
How Wegovy Works: GLP-1 Mechanism for Weight Loss
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to support weight management. The medication works primarily by reducing appetite and promoting earlier satiety signals, helping you feel satisfied with smaller meal portions. Unlike Mounjaro's dual hormone approach, Wegovy focuses specifically on GLP-1 pathways, providing targeted appetite control through brain receptors. The once-weekly injection schedule maintains consistent hormone levels, reducing food cravings throughout the week. Additionally, Wegovy may slow gastric emptying, contributing to prolonged feelings of fullness after eating. This focused mechanism makes it particularly suitable for patients who respond well to pure GLP-1 stimulation without requiring additional hormonal pathways.
EverydayMeds Ordering Process: Seamless Switching Between Treatments
Switching to Wegovy or Mounjaro for weight loss through EverydayMeds begins with our streamlined 3-minute online clinical assessment, designed to capture your current treatment history and switching rationale. Our registered prescribers (GPhC #9012878) review your application within 3 working days, or choose express 24-hour review for urgent switches. The assessment specifically addresses dose conversion between medications, ensuring safe transition protocols are followed. Once approved, both Wegovy and Mounjaro ship via next-day delivery using cold-chain temperature-controlled packaging. Our pharmacy team coordinates timing to minimise treatment gaps, particularly important when switching between different injection schedules to maintain consistent appetite control.
Storage and Practical Considerations When Choosing Wegovy or Mounjaro
Storage requirements often influence choice between Wegovy or Mounjaro for weight loss, particularly for frequent travelers or those with limited refrigeration access. Wegovy offers superior flexibility with 6 weeks room temperature stability below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limitation. Both use pre-filled FlexTouch pen systems, though dose escalation schedules differ—Wegovy follows a standard 4-week progression (0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg), while Mounjaro uses 2.5mg → 5mg → 7.5mg → 10mg → 15mg increments. The prescription-only medicine protocols require regular prescriber monitoring regardless of choice. Wegovy's established 2.4mg maintenance dose provides clear treatment endpoints, while Mounjaro's higher maximum doses offer additional escalation options if needed. Both require refrigeration at 2-8°C before first use and should never be frozen or shaken vigorously.
Dose Conversion Guide: Safe Switching Between Wegovy and Mounjaro for Weight Loss
Converting between Wegovy or Mounjaro for weight loss requires careful prescriber supervision, as the medications use different active ingredients with distinct potency profiles. While no official conversion chart exists, experienced clinicians typically consider current dose, treatment duration, and individual response patterns when transitioning patients. Switching usually involves starting the new medication at an appropriate introductory dose rather than attempting direct equivalency, minimising side effects while maintaining appetite control benefits.
Timing coordination becomes crucial when switching—your prescriber may recommend a brief washout period or overlapping transition depending on your current regimen. EverydayMeds' clinical team works closely with your prescriber to ensure seamless supply timing, preventing treatment interruptions that could compromise your weight management progress. Both medications require gradual dose escalation, so switching often means restarting the titration process rather than jumping to equivalent strengths immediately.
Why EverydayMeds for Your Wegovy or Mounjaro Weight Loss Journey
EverydayMeds uniquely positions itself as the comprehensive solution for patients considering Wegovy or Mounjaro for weight loss, stocking both medications through our GPhC-registered pharmacy (#9012878). Our clinical team understands the complexities of switching GLP-1 treatments, providing expert guidance throughout your transition process. With transparent pricing, genuine discount codes (FIRST40 for new customers, DOSE25 for returning), and next-day cold-chain delivery, we eliminate the logistical challenges of changing treatments. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment today. Whether you're switching due to cost, availability, or clinical reasons, our comprehensive support ensures continuity in your weight management journey without compromising treatment quality or safety standards.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
